A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Trial Profile

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs ONCOS 102 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Acronyms MESOS
  • Sponsors Targovax
  • Most Recent Events

    • 11 Dec 2017 According to a Targovax media release, the company expects to release immune response data in a subset of patients in February 2018.
    • 11 Dec 2017 According to a Targovax media release, this trial has successfully passed the first planned independent safety review and was recommended to be continued as planned by the review committee.
    • 02 Nov 2017 According to a Targovax media release, interim data expected in H2 2017 and clinical, immune and safety data in H1 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top